A novel benzamide derivative SY-15 inhibits multiple myeloma cell proliferation

Abstract

Aim: Over the past two decades, the natural course of multiple myeloma (MM) has changed significantly, primarily due to the emergence of novel therapeutic agents targeting the bone marrow microenvironment (BMM). Despite these advancements, the underlying mechanisms of drug resistance remain largely unclear. In this study, the effects of a novel benzamide derivative, SY-15, on MM cell lines were investigated, and the findings suggest that this molecule could be a promising anticancer drug candidate, warranting further research.

Materials and Methods: Multiple myeloma (MM) cell lines (MM1S, U266, H929, RPMI8226) were cultured, and the effects of various concentrations of a novel benzamide derivative on cell viability were evaluated using the MTT assay. 

Results: The anticancer activity of the SY-15 molecule was evaluated in multiple myeloma (MM) cell lines following 72 hours of treatment, and for comparison, in the L929 normal fibroblast cell line. A statistically significant difference in cell viability percentages was observed among the five cell lines (p<0.001). The median cell viability percentage was 93.6247 for the L929 cell line, 44.4110 for the MM1S cell line, 22.4655 for H929, 31.7180 for U266, and the lowest median value was recorded in the RPMI 8226 cell line at 13.0931. Notably, SY-15 did not exhibit significant cytotoxicity in L929 fibroblast cells.

Conclusion: SY-15 has the potential to be an effective anticancer agent with high selectivity and low toxicity for the treatment of MM. It may offer a novel therapeutic option, particularly for patients who have developed resistance to other MM drugs.